EA201592082A1 - 3,4-дигидроизохинолин-2(1h)-ильные соединения - Google Patents

3,4-дигидроизохинолин-2(1h)-ильные соединения

Info

Publication number
EA201592082A1
EA201592082A1 EA201592082A EA201592082A EA201592082A1 EA 201592082 A1 EA201592082 A1 EA 201592082A1 EA 201592082 A EA201592082 A EA 201592082A EA 201592082 A EA201592082 A EA 201592082A EA 201592082 A1 EA201592082 A1 EA 201592082A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
isohinolin
ily
dihydro
formula
Prior art date
Application number
EA201592082A
Other languages
English (en)
Other versions
EA029220B1 (ru
Inventor
Кристофер Дэвид Бидл
Дэвид Эндрю Коатес
Цзюньлян Хао
Джозеф Херман Крушински Джр.
Мэттью Роберт Рейнхард
Джон Менерт Шаус
Крэйг Дэниел Волфанджел
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201592082A1 publication Critical patent/EA201592082A1/ru
Publication of EA029220B1 publication Critical patent/EA029220B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

В настоящем изобретении предложены определенные 3,4-дигидроизохинолин-2(1H)-ильные соединения, в частности соединения формулы I, и их фармацевтические композиции. В настоящем изобретении также предложены способы применения соединения формулы I для лечения когнитивных нарушений, связанных с болезнью Паркинсона или шизофренией.
EA201592082A 2013-05-30 2014-05-27 3,4-дигидроизохинолин-2(1h)-ильные соединения в качестве положительных аллостерических модуляторов (pam) допаминового рецептора d1 EA029220B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828740P 2013-05-30 2013-05-30
US201361905329P 2013-11-18 2013-11-18
PCT/US2014/039494 WO2014193781A1 (en) 2013-05-30 2014-05-27 3,4-dihydroisoquinolin-2(1h)-yl compounds

Publications (2)

Publication Number Publication Date
EA201592082A1 true EA201592082A1 (ru) 2016-04-29
EA029220B1 EA029220B1 (ru) 2018-02-28

Family

ID=50983199

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592082A EA029220B1 (ru) 2013-05-30 2014-05-27 3,4-дигидроизохинолин-2(1h)-ильные соединения в качестве положительных аллостерических модуляторов (pam) допаминового рецептора d1

Country Status (38)

Country Link
US (1) US8962654B2 (ru)
EP (1) EP3004061B8 (ru)
JP (2) JP6130590B2 (ru)
KR (1) KR101808933B1 (ru)
CN (1) CN105228985B (ru)
AP (1) AP2015008867A0 (ru)
AU (2) AU2014274435B2 (ru)
BR (1) BR112015029090B1 (ru)
CA (1) CA2912849C (ru)
CL (1) CL2015003444A1 (ru)
CR (1) CR20150622A (ru)
CY (1) CY1119361T1 (ru)
DK (1) DK3004061T3 (ru)
DO (1) DOP2015000289A (ru)
EA (1) EA029220B1 (ru)
ES (1) ES2647086T3 (ru)
GT (1) GT201500334A (ru)
HK (1) HK1216314A1 (ru)
HR (1) HRP20171696T1 (ru)
HU (1) HUE034607T2 (ru)
JO (1) JO3316B1 (ru)
LT (1) LT3004061T (ru)
ME (1) ME02838B (ru)
MX (1) MX2015016495A (ru)
MY (1) MY180751A (ru)
NZ (1) NZ713809A (ru)
PE (1) PE20152032A1 (ru)
PH (1) PH12015502658B1 (ru)
PL (1) PL3004061T3 (ru)
PT (1) PT3004061T (ru)
RS (1) RS56294B1 (ru)
SG (1) SG11201509310QA (ru)
SI (1) SI3004061T1 (ru)
TN (1) TN2015000514A1 (ru)
TW (2) TWI691489B (ru)
UA (1) UA118759C2 (ru)
WO (1) WO2014193781A1 (ru)
ZA (1) ZA201508213B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010324810B2 (en) 2009-11-27 2016-05-12 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
CA3018352A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
AU2018225556A1 (en) 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
EP3418270A1 (en) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
EP3717025B1 (en) 2017-12-01 2021-11-03 UCB Biopharma SRL Imaging agents
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
AU2019402087B2 (en) 2018-12-18 2023-04-06 Eli Lilly And Company Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
WO2021001286A1 (en) 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2021015873A (es) 2019-07-01 2022-02-03 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
WO2022076418A1 (en) 2020-10-07 2022-04-14 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
CN116507332A (zh) 2020-12-03 2023-07-28 Ucb生物制药有限责任公司 八氢异喹啉基衍生物
MX2023007155A (es) 2020-12-18 2023-06-28 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como un modulador alosterico positivo de d1.
US20240083875A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
IL303688A (en) * 2020-12-18 2023-08-01 UCB Biopharma SRL Amorphous solid dispersions
US20240083925A1 (en) * 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
BR112023018175A2 (pt) 2021-03-08 2023-10-31 Lilly Co Eli Uso de mevidalen e outros moduladores alostéricos d1 positivos no tratamento de alucinações e psicose relacionada à demência
WO2022192255A1 (en) 2021-03-09 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE97893T1 (de) 1988-02-19 1993-12-15 Smithkline Beecham Farma 1,2,3,4-tetrahydroisoquinoline, verfharen zu ihrer herstellung und ihre verwendung als kappa- rezeptor agonisten.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
US20090099158A1 (en) 2007-03-01 2009-04-16 Grice Cheryl A Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
US20140357664A1 (en) 2014-12-04
MY180751A (en) 2020-12-08
BR112015029090A2 (pt) 2017-07-25
KR20160003110A (ko) 2016-01-08
ZA201508213B (en) 2017-08-30
NZ713809A (en) 2019-11-29
CN105228985A (zh) 2016-01-06
TWI691488B (zh) 2020-04-21
MX2015016495A (es) 2016-03-01
CR20150622A (es) 2016-01-06
BR112015029090A8 (pt) 2020-03-17
US8962654B2 (en) 2015-02-24
CY1119361T1 (el) 2018-02-14
CA2912849A1 (en) 2014-12-04
AU2016238934A1 (en) 2016-10-27
DK3004061T3 (en) 2017-10-23
ME02838B (me) 2018-01-20
PL3004061T3 (pl) 2018-01-31
UA118759C2 (uk) 2019-03-11
PH12015502658A1 (en) 2016-03-07
JP6130590B2 (ja) 2017-05-17
KR101808933B1 (ko) 2017-12-13
TW201536745A (zh) 2015-10-01
PT3004061T (pt) 2017-10-19
SG11201509310QA (en) 2015-12-30
HRP20171696T1 (hr) 2017-12-29
SI3004061T1 (sl) 2017-10-30
EA029220B1 (ru) 2018-02-28
EP3004061B8 (en) 2017-10-04
HUE034607T2 (en) 2018-02-28
CN105228985B (zh) 2017-05-10
TW201940469A (zh) 2019-10-16
AU2016238934B2 (en) 2017-08-03
JP2016520127A (ja) 2016-07-11
LT3004061T (lt) 2017-11-27
PH12015502658B1 (en) 2016-03-07
CA2912849C (en) 2017-05-30
EP3004061A1 (en) 2016-04-13
JP6387433B2 (ja) 2018-09-05
TN2015000514A1 (en) 2017-04-06
CL2015003444A1 (es) 2016-07-15
AU2014274435B2 (en) 2016-07-14
BR112015029090B1 (pt) 2023-05-09
JP2017178945A (ja) 2017-10-05
AU2014274435A1 (en) 2015-11-19
DOP2015000289A (es) 2015-12-31
PE20152032A1 (es) 2016-01-28
TWI691489B (zh) 2020-04-21
WO2014193781A1 (en) 2014-12-04
JO3316B1 (ar) 2019-03-13
EP3004061B1 (en) 2017-08-30
ES2647086T3 (es) 2017-12-19
GT201500334A (es) 2018-11-23
RS56294B1 (sr) 2017-12-29
HK1216314A1 (zh) 2016-11-04
AP2015008867A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
IN2015DN01156A (ru)
GEP20166554B (en) Nitrogenated heterocyclic compound
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX366308B (es) Derivados de amida como bloqueadores de ttx-s.
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
IN2014DN09826A (ru)
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
AR096310A1 (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo
GEP201606554B (en) Nitrogenated heterocyclic compound

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG TJ TM